Chinese pharma company spanning prescription drugs, diabetes/endocrine care and medical aesthetics (fillers, devices).
Chinese pharma company spanning prescription drugs, diabetes/endocrine care and medical aesthetics (fillers, devices).
Resells other makers' drugs to hospitals and pharmacies, which brings in the most revenue at thin margins, while its own prescription drugs, including diabetes treatments, and its aesthetics products carry most of the profit. Aesthetics are mostly paid for by consumers rather than insurance, which keeps that line outside government drug-price controls.
In one line: A Chinese Allergan-meets-Novo Nordisk generics hybrid.
Moat: narrow (brand, distribution). Established hospital sales network plus a fast-growing aesthetics distribution and device business.
Headquarters: Hangzhou, China · Founded: 1993 · Employees: 19,095
Size Huadong Medicine (000963.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $6.69B, the 350th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥25.62 on 18 Nov 2026.
Performance Over six months the shares fell 18.1%, against -1.8% for the median peer and -20.0% for the China market (cap-weighted) — 6th lowest of 20 in its peer set.
Growth Revenue grew 2.4% over the last twelve months (peer median +16.4%); the operating margin is 9.2% (peer median 14.1%).
Valuation It trades at 12.5× forward earnings against a peer median of 21.6× (3rd cheapest of 15).
Price implies For today's price to make sense, revenue must grow about -4% a year for seven years (Req g). Recent delivered growth is +5%, so the hurdle is -9 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 6.9 points above its cost of capital (6.2% WACC).
Next results Next results expected around 22 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥44.0B | CN¥43.4B | CN¥41.7B | CN¥40.4B | CN¥37.5B |
| Revenue growth | — | +4% | +3% | +8% | — |
| Gross profit | CN¥14.4B | CN¥13.4B | CN¥13.3B | CN¥12.6B | CN¥11.5B |
| EBITDA | n/a | CN¥5.16B | CN¥5.18B | CN¥4.41B | CN¥3.86B |
| Net income | CN¥3.44B | CN¥3.41B | CN¥3.51B | CN¥2.84B | CN¥2.50B |
| Free cash flow | CN¥2.30B | CN¥2.74B | CN¥2.07B | CN¥2.42B | CN¥1.29B |
| Capital expenditure | CN¥1.24B | CN¥1.57B | CN¥1.73B | CN¥1.61B | CN¥1.19B |
| Total debt | CN¥5.67B | CN¥5.03B | CN¥5.65B | CN¥3.74B | CN¥3.70B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Huadong Medicine 000963.SZ | $6.69B | -18% | +2% | 9% | 12.5× | -3.9% |
| Sbp 1177.HK | $12.2B | +5% | +15% | 30% | 17.5× | -5.7% |
| IMEIK Technology Development 300896.SZ | $3.66B | -25% | -7% | 45% | 22.4× | 17.5% |
| Bloomage Biotechnology 688363.SS | $2.27B | -21% | -22% | 5% | 52.0× | 19.0% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 000963.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -4.1% | +1.7% | 9th lowest of 21 |
| 6-month return | -18.1% | -1.8% | 6th lowest of 20 |
| Distance from 52-week high | -41.5% | -20.5% | 8th lowest of 21 |
| Revenue growth (TTM) | +2.4% | +16.4% | 4th lowest of 18 |
| Operating margin | 9.2% | 14.1% | 6th lowest of 19 |
| Forward P/E | 12.5× | 21.6× | 3rd cheapest of 15 |
| Growth the price implies (Req g, 7 yrs) | -3.9% | 6.6% | 4th least demanding of 11 |
| Growth delivered (Del g) | +5.3% | +12.3% | 2nd lowest of 11 |
| Hurdle (Req g minus delivered) | -9.2 pp | -11.9 pp | 6th least demanding of 11 |
| ROIC minus cost of capital | +6.9 pp | -0.8 pp | 5th highest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Huadong Medicine 000963.SZ | China | $6.69B | -18% | +2% | 9% | 12.5× | -3.9% | +5.3% |
| Alkem Laboratories ALKEM.NS | India | $6.69B | -5% | +13% | 17% | 27.3× | 25.0% | +10.7% |
| China Resources Sanjiu Medical & Pharmaceutical 000999.SZ | China | $6.59B | +6% | +4% | 14% | 13.2× | -6.2% | +18.4% |
| Apotex Health APTX.TO | Canada | $6.56B | n/a | +4% | 32% | 19.3× | -11.9% | +4.2% |
| Oruka Therapeutics ORKA | United States | $6.49B | +58% | n/a | n/a | n/a | n/a | n/a |
| Samsung Epis 0126Z0.KS | South Korea | $6.49B | -31% | n/a | 12% | 23.8× | n/a | n/a |
| Belite Bio, Inc. ADR BLTE | United States | $6.41B | +9% | n/a | n/a | n/a | n/a | n/a |
| Akeso 9926.HK | Hong Kong | $7.01B | -48% | +42% | -25% | n/a | n/a | n/a |
| Bachem BANB.SW | Switzerland | $7.06B | 0% | +5% | 19% | 32.4× | n/a | n/a |
| Biocon BIOCON.NS | India | $6.31B | -15% | +6% | 8% | 61.3× | n/a | n/a |
| Asymchem Laboratories (Tianjin) 6821.HK | Hong Kong | $7.10B | +17% | +24% | 17% | 24.4× | n/a | n/a |
| RemeGen 688331.SS | China | $6.28B | -24% | +272% | 61% | 10.8× | 1.1% | +303.3% |
| ImmunityBio IBRX | United States | $7.13B | -17% | +121% | -150% | n/a | n/a | n/a |
| Cytokinetics CYTK | United States | $7.15B | -35% | +30% | -625% | n/a | n/a | n/a |
| ONO Pharmaceutical 4528.T | Japan | $7.33B | -2% | -2% | 22% | 15.3× | -6.8% | +10.8% |
| Mirum Pharmaceuticals MIRM | United States | $6.04B | -5% | +42% | -21% | n/a | n/a | n/a |
| Corcept Therapeutics CORT | United States | $7.42B | +15% | +30% | 12% | 15.3× | 23.9% | +16.6% |
| Supernus Pharmaceuticals SUPN | United States | $6.02B | -41% | +16% | 45% | 8.0× | 6.2% | +13.9% |
| Kiniksa Pharmaceuticals International KNSA | United States | $7.47B | +75% | +58% | 14% | 56.6× | 10.4% | +45.5% |
| Grifols GRF.MC | Spain | $7.48B | +19% | +1% | 16% | 13.1× | 7.1% | +7.1% |
| Ligand Pharmaceuticals LGND | United States | $5.98B | +37% | +1% | 14% | 27.3× | 57.7% | +7.5% |